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Introduction
Cardiovascular disease is the leading cause of human morbidity 
and mortality. Ischemic cardiomyopathy1 (ICM) affects approxi-
mately one out of 100 people in the United States, most often 
middle-aged to elderly men. ICM is the most common form of 
cardiomyopathy leading to dilation of the cardiac chambers and 
congestive heart failure. In spite of great efforts, molecular mark-
ers and targets of ICM are not currently well understood.2 The tis-
sue-specific pathogenesis pathways in the human heart reportedly 
include approximately 20 genes3 coding for structural proteins 
and those associated with Ca2+ homeostasis and energy metabo-
lism. However, some of the implicated genes may be secondary to 
ICM because intrinsic noise of investigative platforms precludes 
from detecting low-signal cell-type-specific critical targets at the 
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whole-tissue level. Different cell types remodel in the develop-
ment and disease following their unique program. Moreover, this 
remodeling is anatomically heterogeneous. To overcome these 
problems and characterize ICM-induced molecular remodeling 
in a cell-type and anatomical region-specific fashion, we com-
bined two technological innovations, laser-capture microdissec-
tion of cells of interest and microarray optimized for detection 
of alternative RNA splicing events in a narrow catalog of genes 
coding for ion channels, exchangers and pumps (CE&P genes), 
which comprise the most acclaimed target classes for top-selling 
prescription drugs. Because CE&P molecules are involved in 
electrical, signaling and mechanical functions of the heart, their 
remodeling in ICM may result in decreased cardiac contractile 
functions.4 It is likely that pathophysiological conditions of ICM 
affect regulation of expression of CE&P splice variants.5 Thus, 
existing molecular knowledge base of cardiovascular diseases is rudimentary because of lack of specific attribution to 
cell type and function. The aim of this study was to investigate cell-specific molecular remodeling in human atrial and 
ventricular myocytes associated with ischemic cardiomyopathy. Our strategy combines two technological innovations, 
laser-capture microdissection of identified cardiac cells in selected anatomical regions of the heart and splice microarray 
of a narrow catalog of the functionally most important genes regulating ion homeostasis. We focused on expression of 
a principal family of genes coding for ion channels, exchangers and pumps (Ce&p genes) that are involved in electrical, 
mechanical and signaling functions of the heart and constitute the most utilized drug targets. We found that (1) Ce&p 
genes remodel in a cell-specific manner: ischemic cardiomyopathy affected 63 Ce&p genes in ventricular myocytes and 
12 essentially different genes in atrial myocytes. (2) Only few of the identified Ce&p genes were previously linked to 
human cardiac disfunctions. (3) The ischemia-affected Ce&p genes include nuclear chloride channels, adrenoceptors, 
cyclic nucleotide-gated channels, auxiliary subunits of Na+, K+ and Ca2+ channels, and cell-surface Ce&ps. (4) In both 
atrial and ventricular myocytes ischemic cardiomyopathy reduced expression of CACNG7 and induced overexpression of 
FXYD1, the gene crucial for Na+ and K+ homeostasis. Thus, our cell-specific molecular profiling defined new landmarks for 
correct molecular modeling of ischemic cardiomyopathy and development of underlying targeted therapies.
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different CE&P subsets and only four indicated genes may be 
common among the ones affected by these diseases, overexpres-
sion of FXYD1 being the most obvious characteristic feature.
Discussion
Our study is based on the precept that to characterize the ICM-
induced molecular remodeling it is essential to investigate it at 
the level of cells and molecules responsible for altered cardiac 
function. To achieve this goal, we developed the investigative 
approach combining laser capture microdissection of identi-
fied cardiac cells from tissue biopsies with splice microarray of 
custom-narrowed sets of CE&P genes that play ultimate role in 
cardiac contraction targeted by ICM. Our approach for the first 
time enabled direct comparison of altered gene expression caused 
by ICM in atrial and ventricular myocytes and identified new 
essential players.
First of all, we found that atrial and ventricular myocytes 
remodel following their unique programs where ICM affects dif-
ferent CE&P genes. Although some of these genes were already 
reported to be expressed in the heart4,79 (see also refs. in Tables 
3 and 4), only few of them were previously linked to known 







-adrenoceptors whose downregulation in cardiomyopathy was 
linked to pathological remodeling in failing ventricular myocar-





1.4 may underlie the slower kinetics of the I
to
 K+ current.40 (3) 
KCND3. Downregulation of cardiac K
V
4.3 and minK channels 
may be associated with arrhythmia and atrial fibrillation.14,61,62,86 
It was reported that congestive heart failure and hypertrophy 
decrease K
V
4.3 expression in terminally failing human hearts.87 In 
line with this finding, KCND3 gene transfer abrogates the hyper-
trophic response to aortic stenosis.88 (4) HCN2. Transfer of this 
gene was also tested as gene therapy for cardiac arrhythmias in 
experimental animals with positive results.89 However, the exist-
ing knowledge base remains rudimentary in the absence of attri-
bution to certain cardiac cell types and functions.





5 channel isoforms and Na+,K+-ATPase but rather affects 
some of their accessory subunits. The most profound change in 
both atrial and ventricular myocytes was overexpression of phos-
pholemman. Binding of phospholemman to Na+,K+-ATPase 
induces a decrease in the affinity of α1-β1 and α2-β1 isozymes 
to external K+ and approximately 2-fold decrease in the affinity to 
internal Na+.90 Inhibition of Na+/Ca2+ exchanger by phospholem-
man91 may add to the disbalance of Na+, K+ and Ca2+ gradients 
across the plasma membrane and contribute to hypertrophy of 
ICM muscle cells due to overexpression of FXYD1. Another unex-
pected finding that may have profound functional consequences 
is underexpression of Na
V
β1. Although the functional role of this 
single-membrane-spanning-repeat protein in the heart remains 
uncertain, it co-localizes with the Na
V
1.5 pore-forming α1 subunit 
in the T-tubule system and intercalating discs levels in cardiomyo-
cytes17 and modulates Na
V
1.5 channels in the heart by increasing 
the Na+ current density.92 Confirming its crucial role in the heart, 
SCN1B knock-out caused prolongation of QT and RR intervals93 
molecular profiling of disease-induced CE&P remodeling may 
narrow the search for crucial players and enable better under-
standing of underlying disease mechanisms and effective ICM 
prevention and treatment. We focused our research on CE&P 
molecular remodeling in atrial and ventricular cardiomyocytes 
because of their ultimate role in cardiac contraction targeted by 
ICM. This research strategy addressed the complexity of cardio-
vascular system and tissue heterogeneity complicated by differen-
tial gene expression and splice variation. Our findings associate 
ICM with altered expression of CACNG7 and FXYD1 in atrial 
and ventricular myocytes and show that these cells remodel in 
ICM following their unique programs involving different subsets 
of CE&P genes.
Results
Laser capture microdissection is an established method for iso-
lation with confidence of histochemically identified cells from 
heterogeneous cell populations allowing the rational design of 
comprehensive splice variant profiling of CE&P remodeling in 
cardiomyocytes. Results of microarray analysis are presented in 
Table 3 and summarized in Table 4. We found that ICM caused 
remodeling of 12 genes in atrial myocytes. Increased expression 
in relation to healthy hearts was found for the FXYD1 gene cod-
ing for protein regulator of Na+,K+-ATPase phospholemman 
(2.3-fold) and intracellular chloride channels CLIC1 and CLIC4 
(both 1.6-fold). The other nine identified genes were significantly 
downregulated including FXYD7, the inward rectifier K
ir
2.4 
channel, the acetylcholine receptor α10 subunit, the Ca2+ chan-
nel Ca
v
γ subunits, the AMPA-selective glutamate receptor 3, the 
K
V
4.3 K+ channel involved in initial phase of repolarization and 
setting the plateau voltage of the action potential, the polyunsat-
urated fatty acids-activated and mechano-sensitive K
2P
4.1 chan-
nel, the Na+ channel Na
V
β1 subunit. In ventricular myocytes we 
identified 63 genes affected by ICM. An increase (2.5-fold) was 
found only for FXYD1. The other 62 CE&P genes were downreg-
ulated 1.5–3.5 fold. Some of them belong to the same functional 
groups that are affected by ICM in atrial myocytes (Table 4) 
including FXYD3, three A-type K+ channels, two inward rectifi-
ers, three tandem-pore-domain K+ channels, three Ca
V
γ subunits, 
six acetylcholine receptor subunits, and the AMPA1 glutamate 
receptor. In addition, we identified three delayed rectifiers, the 
Ca2+-activated K
Ca
3.1 channel, seven modifiers and β-subunits of 
K+ channels, six voltage-gated Ca2+ channels, two ENaC and trp 
channels, cyclic nucleotide-gated channels HCN2 and CNGA3, 
three connexins, NMDA and glycine receptors, GABA receptor 
subunits and three adrenoceptors.
To find out whether the splice microarray results reported in 
Table 3 are disease-type specific, we supplemented the same splice 
microarray of ICM ventricular myocytes with one additional 
sample prepared from left ventricle of a 41-years old dilated car-
diomyopathy male donor. The top-list ANOVA gene score anno-
tation for combined altered CE&P genes in ventricular myocytes 
(Table 3) was reduced from 63 to just 4 genes (FXYD1 (G
fold
 = 
+2.4), HCN2 (-1.5), GLRA1 (-1.8) and GJC1 (-2.3)). This result 
suggests that dilated and ischemic cardiomyopathy may affect 
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in St. Louis, MO. Healthy hearts were excluded from trans-
plantation after exceeding 6 h-limit of allograft ischemic time. 
Showing no evidence of hemorrhagic stroke, they retained nor-
mal structure and function evidenced by bimodal biophotonic 
imaging and optical mapping of the atrioventricular junction.100 
There was no delay in collecting donor’s heart tissue. Decision 
on suitability for transplantation was made prior to harvest of 
organs, our team members were notified in advance (at least 2 
h before cross clamping) and were present during organ harvest. 
Heart was cardioplegically arrested, harvested and transferred 
to us immediately after removal from the chest. Tissue samples 
(0.5–2 g) were dissected from the area outside of scar burden (if 
any) of left ventricle and left atrial appendages under cold cardio-
pledic arrest conditions within approximately 30–40 min after 
removal of the heart from donor’s chest. Tissue was washed in 
4°C saline, immersed in Tissue-Tek OCT Compound (Electron 
Microscopy Sciences, Hatfield, PA), flash frozen in liquid nitro-
gen and stored at -80°C until use. Although availability of donors 
suitable for this study was limited, the number of selected human 
hearts (Tables 1 and 2) is in full compliance with the NCBI-
recommended MIAME guidelines to microarray101 and enabled 
us to analyze all individual donor’s samples, grouped by cell type, 
simultaneously on one microarray slide, thus excluding possible 
slide-to-slide variations.
Laser-capture microdissection and isolation of mRNA. Serial 
cryostat sections (7–8 µm thick) were cut from the frozen tissue 
samples using Minotome Plus microtome cryostat. Before laser-
capture microdissection, cardiomyocytes in the sections were 
quickly (10 s) stained with Eosin Y (Sigma-Aldrich, St. Louis, 
MO) according to standard procedure. Given the notably large 
size of cardiac muscle cells relative to other cells in the tissue, 
this method of identification is sufficient to distinguish stained 
cardiomyocytes from other cells under microscope. Laser-capture 
microdissection was performed with PixCell II system (Arcturus, 
Mountain View, CA) using a 7.5-µm laser spot as described ear-
lier.5 The excised cardiomyocytes were picked up from the slide 
and development of cardiomyopathy.94 Post-transcriptional gene 
silencing of Na
V
β1 reduced mRNA and protein levels of Na
V
1.5, 
KChIP2 mRNA and K
V
4.3 resulting in markedly decreased Na+ 
and I
to
 currents.95 Thus, underexpression of Na
V
β1 may lead to 
a suppression of I
to
, action potential prolongation and increased 
susceptibility of the heart to ventricular arrhythmia.
Other new potential targets for drug discovery are CLICs.8,35 
Members of the p64 family, CLIC proteins localize to the cell 
nucleus and exhibit both nuclear and plasma-membrane chloride 
channel activity, but their functions are not well defined. CLIC2, 
which shares sequence similarity with CLIC1, modulates cardiac 
ryanodine receptors and inhibits Ca2+ release from the sarcoplas-
mic reticulum.96 Thus, ICM-induced remodeling of CLICs in 
cardiomyocytes may affect membrane potential, intracellular pH 
and cell volume.
The four identified Ca
V
γ calcium channel subunits downregu-
lated in ICM show a broad spectrum of modulating activities that 
may have a role in cardiac myocytes. The γ7, which is homologous 
to γ5, regulates stability of certain mRNAs97 and, along with γ2 
and γ8, controls trafficking and gating of AMPA receptors.98,99 It 
remains to be studied whether remodeling of AMPA receptors in 
ICM is associated with Ca
V
γs. Acetylcholine,72 AMPA and NMDA 
receptors,73 also downregulated in ICM, are present in cardiac neu-
romuscular junctions and intercalating disk, but little is known 
about their non-neuronal expression and roles in the heart.
Our study is the first step in molecular characterization of ICM 
with organ- and cell-specific annotation of altered expression of 
CE&P genes. Our study does not determine whether upregula-
tion or downregulation of the identified CE&P genes are the pri-
mary drivers of ICM or reflect pathophysiological response to the 
disease. However, it provides an objective context within which it 
would be easier to find therapeutic targets among the elucidated 
markers of ICM. Future extension of this study may clarify links 
between CE&P genes expression and drug therapy, duration of 
disease, age, gender and race as potential factors in ICM and 
define key aspects of the principal gene network in relation to 
the development of ICM at the cellular and specific intercellular 
levels. In conjunction with protein and immunohistochemical 
analyses this may yield a more robust approach to better under-
standing mechanisms and pathophysiology of ICM—a critical 
need in the clinical utilization of this field.
Methods
Human cardiac tissue samples. Healthy (Table 1) and ICM 
hearts (Table 2) of anonymous donors were obtained from the 
Cardiac Transplantation Center at the Washington University 
Table 1. Characteristics of the healthy heart donors
Patient # Age Sex Cause of death
Cardiac tissue 
studied
h1 58 F Intracerebral hemorrhage LV
h2 70 M Intracerebral hemorrhage LV, LAA
h3 40 M Brain tumor LV
h4 72 F Intracerebral hemorrhage LAA
h5 58 M Intracerebral hemorrhage LAA
LV, left ventricle; LAA, left atrium appendage.
Table 2. Characteristics of the ICM heart patients
Patient # Age Sex
Complications and prior 
 treatment
PR (ms) HR (bpm) QRS (ms) EF (%)
D1 54 M CABG, VT, ICD 184 100 202 ND
D2 46 M VF, ICD 216 91 106 19
D3 50 M ICD 128 128 144 25
CABG, coronary artery bypass graft; ICD, implantable cardioverter defibrillator; QRs, a waveform on eKG which represents excitation of the ventricles; 
eF, ejection fraction; ND, not determined.
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surface and captured on LCM Caps. To confirm the quality of 
cell isolation, the sectional images taken before and after micro-
dissection were thoroughly inspected to exclude contamination 
with non-muscle cells, and only then the captured samples from 
serial sections were joined together. High-quality cellular RNA 
was recovered from the collected cells using PicoPureTM RNA 
isolation kit (Arcturus) and treated with RNase-free DNase 
(Qiagen, Valencia, CA). Quality of RNA was tested right before 
the labeling for microarray by measuring the OD and 28S/18S 
Table 3. Top-list ANOVA gene-score annotation for Ce&p genes altered 











FXYD16,7 NM_021902 h75358 0.02859 2.3
CLIC18 NM_001288 BU173816 0.04412 1.6
CLIC48 NM_013943 BG436443 0.04047 1.6
KCNJ149,10 NM_013348 na 0.01289 -1.6†
FXYD7 NM_022006 CQ722304 0.01907 -1.6
CHRNA1011 NM_020402 CR744383 0.02780 -1.6
CACNG712 NM_031896 h19702 0.01039 -1.6
GRIA313 NM_000828 DA531074 0.01945 -1.7
KCND314 NM_004980 NM_172198 0.00837 -1.7
KCNK49,15 NM_016611 Be900958 0.01063 -1.8
SCN1B16-18 NM_001037 DA062026 0.03059 -1.8
CACNG2 NM_006078 na 0.02046 -4.7
Ventricular myocytes
FXYD16,7 NM_021902 h75358 0.00511 2.5
KCNN4 NM_002250 AL552182 0.00551 -1.5
CLCN2 NM_004366 BM789394 0.00391 -1.5
CACNG7 NM_031896 h19702 0.00069 -1.5
CACNG8 NM_031895 CQ718803 0.00092 -1.5
CACNA1A NM_000068 BF529475 0.01245 -1.5
KCNH6 NM_173092 CQ730511 0.00758 -1.5
CACNG5 NM_145811 AX101266 0.03112 -1.5
GRIN2A NM_000833 BG718790 0.01562 -1.5
SCNN1D NM_002978 AK093372 0.00046 -1.6†
GABRA3 NM_000808 DA801686 0.00407 -1.6
CACNA1E19,20 NM_000721 L27745 0.00148 -1.6 
KCNH19,21,22 NM_172362 DB021985 0.00092 -1.6
KCNV29,23 NM_133497 CQ724488 0.00935 -1.6
CHRNA6 NM_004198 DA415543 0.00817 -1.6
KCNK69,24 NM_004823 AW883970 0.02392 -1.6
CFTR25 NM_000492 BG386556 0.00212 -1.6
GLRA3 NM_006529 BG186165 0.00657 -1.6
TRPC426,27 NM_016179 AF421361 0.02904 -1.6
FXYD3 NM_021910 DR006067 0.01264 -1.6†
GRIN2D NM_000836 AB209292 0.00249 -1.6†,‡
CACNA1D9,28,29 NM_000720 CQ731466 0.00347 -1.7
HCN29,30 NM_001194 BX281160 0.00039 -1.7
KCNS19 NM_002251 DA231979 0.02663 -1.7
KCNK1831 NM_181840 AX319992 0.00469 -1.7
VMD232 NM_004183 AA205892 0.03238 -1.7
TRPM133 NM_002420 na 0.02334 -1.7
CHRND34 NM_000751 BF306695 0.01945 -1.7†
CLIC335 NM_004669 Be902424 0.01425 -1.7†
CACNA1H36,37 NM_021098 DB100395 0.00183 -1.7
CACNA1G29 NM_198396 BM451648 0.00045 -1.7
Table 3. (continued)  
KCND238-40 NM_012281 DA125095 0.01268 -1.7
CNGA3 NM_001298 AK131300 0.02203 -1.7
GABRG2 NM_198904 BI819259 0.02867 -1.8
KCNA49,28,39-41 NM_002233 CQ741592 0.02019 -1.8
ADRA1B42 NM_000679 na 0.02796 -1.8†
CHRNA4 NM_000744 BC096291¶ 0.00353 -1.8
CACNA1I NM_021096 AX068892 0.00270 -1.8
GRIA1 NM_000827 DA749477 0.01665 -1.8
KCNJ19,43 NM_153767 NM_000220 0.00360 -1.8
KCNC39,28 NM_004977 BM474777 0.00913 -1.8
KCNQ49,44 NM_004700 AK074957 0.02336 -1.9
KCNMB245 NM_181361 BG185231 0.01402 -1.9
GABRG1 NM_173536 CQ714573 0.02843 -1.9
KCNG146 NM_172318 DA497732 0.02389 -1.9
KCNE114,47,48 NM_000219 AY789480 0.01744 -1.9
GLRA1 NM_000171 Bp208426 0.01999 -2.0
CHRNA1 NM_000079 CD013888 0.02807 -2.0†
NOX149 NM_013954 NM_013955 0.00356 -2.0
GRID2 NM_001510 DB052812 0.00299 -2.0
CHRNA9 NM_017581 BF513332¶ 0.00625 -2.0
ADRA2C50-53 NM_000683 T39448 0.00030 -2.1†
GJB1 NM_000166 BF571436 0.01233 -2.1
GABRR1 NM_002042 CB959800 0.01415 -2.1
SCNN1G9 NM_001039 CQ721445 0.00501 -2.2
CNGB3 NM_019098 BX104558 0.00254 -2.5
CHRNB3 NM_000749 DA127065 0.00064 -2.5
GJC154 NM_152219 na 0.00582 -2.5
ADRB152,55,56 NM_000684 na 0.00674 -2.5
KCNG4 NM_172347 CQ728641 0.01073 -2.8
KCTD11 NM_00100291 na 0.00300 -3.1†
KCNA29,16,28,57 NM_004974 BI907383 0.00795 -3.1
GJB6 NM_006783 AY789474 0.00040 -3.5
*A two-way ANOVA model was used to compare ICM vs. healthy (h) 
cardiac samples as described in splice microarray data analysis. p-
values, geometric mean (Gmean), and the respective Gfold Change values 
were calculated. †partial (tiling) human cardiac cDNA clones: AI082799 
(KCNJ14); DA560890 (SCNN1D); AI138642, AI144215 and AI183491 
(FXYD3); AA455065 (GRIN2D); AA716738 and AI367583 (CHRND); W69541, 
AI146716 and W69457 (CLIC3); AA010313 (ADRA1B); W81677 (CHRNA1); 
AAB31164 (ADRA2C); AJ709249 and AJ711264 (KCTD11). ‡CK845061.1 
cDNA from rat ventricle (GRIN2D). ¶This sequence may represent a 
bonafide polyA tail.
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Microarray data analysis. The statistically significant differ-
ential expression patterns between ICM and healthy atrial and 
ventricular cell samples was analyzed using long- to short-form 
ratio statistics and expression level statistics to identify genes and 
splice events affected by ICM. All analyses were performed at 
ExonHit using Partek Genomics Suite. Principal Component 
Analysis was carried out to illustrate the level of spread between 
samples and experimental groups. A two-way ANOVA model 
was used to perform statistical tests on the probe set level intensi-
ties, to compare ICM vs. healthy cells. A Source of Variation plot 
was generated from this data to find the relative level of differ-
ence contributed by each factor. A cutoff level was determined to 
generate “top hit lists” of probe sets that indicate the most statisti-
cally significant differences between the sample groupings. The 
raw and transformed data sets are submitted to Gene Expression 
Omnibus, accession # GSE17294 and GSE17530. The method 
accounted for specific splice variants shown in the results, but 
did not evaluate the ICM-induced changes in alternative splicing. 
Low variability between the individual RNA samples in mean-
ingful (p < 0.01) probesets, estimated as average of individual 
probesets standard deviations normalized to the respective mean 
values (0.08 ± 0.04, mean ± st.dev), suggests that differences in 
RNA ratios. On average, the OD ratio at 260/280 nm and 
260/230 nm was >1.8 and the ratio of 28S/18S in the RNA 
samples selected for experiments was ≥1.6. Individual samples of 
total RNA were optionally amplified without 3'-bias using the 
TransPlexTM Whole Transcriptome Amplification kit (Rubicon 
Genomics, Ann Arbor, MI). (The non-bias 3'-amplification 
was confirmed by the automated RT-PCR with capillary elec-
trophoretic quantification of amplicons executed on a commer-
cial human cardiac total RNA samples (Sigma) with primers to 
CACNA1C and CACNB2, calcium channel genes characterized 
by complex alternative splicing). The amplified products were 
purified using QIAquick PCR purification kit (Qiagen).
cDNA labeling and microarray. The PCR products were frag-
mented with DNase I, denatured and end-labeled with Cy-3 fluo-
rescent dye. The individual donor’s samples, grouped according to 
cell type, were analyzed simultaneously on Human Ion Channel 
Splice Arrays 8-pack 4 x 44K slides (ExonHit Therapeutics, 
Gaithersburg, MD) manufactured on the Ion Channel Splice 
Array sv1.1 platform representing 287 human CE&P, including 
248 alternatively spliced ones in total 1,655 splicing events and 
supplemented with additional capabilities to recognize connexins 
and ryanodine receptors.
Table 4. Ce&p genes altered by ICM in atrial and ventricular myocytes
CE&P class protein Atrial myocytes Ventricular myocytes
Cl- channel CLIC18, CLIC48 CLIC335, CLCN2*, CFTR25,58,59, VMD232
Transient outward (Ito) K









K+ channel modifiers and β subunits KV6.1 (KCNG1)
46, KV6.3 (KCNG4), KV8.2 (KCNV2)
*9,23, KV9.1 (KCNS1)
9, minK 
(KCNE1)*14,47,48,60-62, tetramerization domain containing 11 (KCTD11)
Inward rectifier K+ channel Kir2.4 (KCNJ14)
*9,10 Kir1.1 (KCNJ1)
*9,43, KV11.2 or heRG2 (KCNH6)




Ca2+-activated K+ channel KCa3.1 (KCNN4)
*, β2 subunit of maxiK (KCNMB2)45
Voltage-gated Ca2+ channel α1 subunit63,64
CaV1.3α1D (CACNA1D)*9,28,29, CaV2.1α1A (CACNA1A)*, CaV2.3α1e 
(CACNA1E)*19,20, CaV3.1α1G (CACNA1G)*65,66, CaV3.1α1h (CACNA1H)*36,37,67, 
CaV3.1α1I (CACNA1I)
Ca2+ channel γ subunit CaVγ2 (CACNG2), CaVγ7 (CACNG7)12 CaVγ5 (CACNG5), CaVγ7 (CACNG7)12, CaVγ8 (CACNG8)
Na+ channel subunits NaVβ1 (SCN1B)*17,18 eNaC-γ (SCNN1G)*9, eNaC-δ (SCNN1D)
TRp channel TRPC426,27,68, melastatin-1 (TRPM1)33
Cyclic nucleotide-gated channel69 HCN2*9,30, CNGA3
Connexin Cx32 (GJB1), Cx30 (GJB6), Cx31.9 (GJC1)54,70,71
Acetylcholine receptor72 α10 (CHRNA10)11 α1 (CHRNA1), α4 (CHRNA4), α6 (CHRNA6), α9 (CHRNA9), β3 (CHRNB3), δ (CHRND)34
Glycine receptor α1 (GLRA1), α3 (GLRA3)
GABA receptor α3 (GABRA3)*, γ1 (GABRG1), γ2 (GABRG2), rho (GABRR1)
NMDA receptor receptor73,74 2A (GRIN2A), 2D (GRIN2D)
Glutamate receptor receptor73,74 AMpA3 (GRIA3)*13 AMpA1 (GRIA1), δ2 (GRID2)
Adrenergic receptor75 α1B (ADRA1B)42,76-78, α2C (ADRA2C)50,52,53, β1 (ADRB1)*52,56
h+ channel NADph oxidase (NOX1)49
Na+,K+-ATpase regulator FXYD1*7, FXYD7 FXYD1*7, FXYD3
*Mouse Genome Database gene expression data (www.informatics.jax.org) confirming expression of the marked genes in mouse heart.
106 Channels Volume 4 Issue 2
MO for help with cardiac tissues. This work was supported in part 
by the Intramural Research Program of the National Institutes 
of Health, National Institute on Aging (Z01 AG000294-08 to 
Nikolai M. Soldatov) and by the National Heart, Lung and Blood 
Institute grant (RO1 HL085369 to Igor R. Efimov).
Note
Supplementary materials can be found at:
www.landesbioscience.com/supplement/GronichCHAN4-2-
Sup.pdf
donor’s age and gender in our study have not notably affected 
the results of microarray. Additional details are presented in 
Supplementary Methods.
Acknowledgements
The authors thank Kevin Becker and William H. Wood (Gene 
Expression and Genomics Unit, NIA) for development of splice 
microarray slides, Heather Jordan and Weiyin Zhou (ExonHit 
Therapeutics) for help with splice microarray analysis, and Cardiac 
Transplantation Unit of the Washington University in St. Louis, 
32. O’Driscoll KE, Hatton WJ, Burkin HR, Leblanc N, 
Britton FC. Expression, localization, and functional 
properties of Bestrophin 3 channel isolated from mouse 
heart. Am J Physiol Cell Physiol 2008; 295:1610-24.
33. Fonfria E, Murdock PR, Cusdin FS, Benham CD, 
Kelsell RE, McNulty S. Tissue distribution profiles of 
the human TRPM cation channel family. J Recep Sign 
Transduct 2006; 26:159-78.
34. Kong B, Liu Y-l, Lü X-d. Microarray-bioinformatics 
analysis of altered genomic expression profiles between 
human fetal and infant myocardium. Chinese Med J 
2008; 121:1257-64.
35. Qian Z, Okuhara D, Abe MK, Rosner MR. Molecular 
cloning and characterization of a mitogen-activated 
protein kinase-associated intracellular chloride channel. 
J Biol Chem 1999; 274:1621-7.
36. Chiang C-S, Huang C-H, Chieng H, Chang Y-T, 
Chang D, Chen J Jr, et al. The Ca
V
3.2 T-type Ca2+ 
channel is required for pressure overload-induced car-
diac hypertrophy in mice. Circ Res 2009; 104:522-30.
37. Cribbs LL, Lee JH, Yang J, Satin J, Zhang Y, Daud 
A, et al. Cloning and characterization of α1H from 
human heart, a member of the T-type Ca2+ channel 
gene family. Circ Res 1998; 83:103-9.
38. Guo W, Jung WE, Marionneau C, Aimond F, Xu H, 





 and results in electrical and molecular remod-
eling, with no evidence of ventricular hypertrophy or 
myocardial dysfunction. Circ Res 2005; 97:1342-50.
39. Marionneau C, Brunet S, Flagg TP, Pilgram TK, 
Demolombe S, Nerbonne JM. Distinct cellular and 
molecular mechanisms underlie functional remodeling 
of repolarizing K+ currents with left ventricular hyper-
trophy. Circ Res 2008; 102:1406-15.
40. Nishiyama A, Ishii DN, Backx PH, Pulford BE, Birks 
BR, Tamkun MM. Altered K+ channel gene expression 





1.4. Am J Physiol Heart Circ Physiol 
2001; 281:1800-7.
41. Kashiwakura Y, Cho HC, Barth AS, Azene E, Marbán 
E. Gene transfer of a synthetic pacemaker channel 
into the heart: A novel strategy for biological pacing. 
Circulation 2006; 114:1682-6.





in heart: Insights from studies of genetically modified 
mice. Clin Exp Pharmacol Physiol 2007; 34:884-8.
43. Shuck ME, Bock JH, Benjamin CW, Tsai TD, Lee 
KS, Slightom JL, et al. Cloning and characterization 
of multiple forms of the human kidney ROM-K potas-
sium channel. J Biol Chem 1994; 269:24261-70.
44. Yeung SY, Pucovsky V, Moffatt JD, Saldanha L, 
Schwake M, Ohya S, et al. Molecular expression and 
pharmacological identification of a role for K
V
7 chan-
nels in murine vascular reactivity. Br J Pharmacol 2007; 
151:758-70.
45. Wallner M, Meera P, Toro L. Molecular basis of fast 
inactivation in voltage and Ca2+-activated K+ channels: 
A transmembrane β-subunit homolog. Proc Natl Acad 
Sci USA 1999; 96:4137-42.
46. Brahmajothi MV, Morales MJ, Liu S, Rasmusson RL, 
Campbell DL, Strauss HC. In situ hybridization reveals 
extensive diversity of K+ channel mRNA in isolated fer-
ret cardiac myocytes. Circ Res 1996; 78:1083-9.
16. Dixon JE, Shi W, Wang H-S, McDonald C, Yu H, 
Wymore RS, et al. Role of the K
V
4.3 K+ channel in ven-
tricular muscle: A molecular correlate for the transient 
outward current. Circ Res 1996; 79:659-68.
17. Domínguez JN, de la Rosa Á, Navarro F, Franco D, 
Aránega AE. Tissue distribution and subcellular local-
ization of the cardiac sodium channel during mouse 
heart development. Cardiovasc Res 2008; 78:45-52.
18. Makita N, Bennett PB Jr, George AL Jr. Voltage-gated 
Na+ channel β
1
 subunit mRNA expressed in adult 
human skeletal muscle, heart and brain is encoded by a 
single gene. J Biol Chem 1994; 269:7571-9.
19. Mitchell JW, Larsen JK, Best PM. Identification of the 
calcium channel α1E (Ca
V
2.3) isoform expressed in 
atrial myocytes. Biochim Biophys Acta—Gene Str Expr 
2002; 1577:17-26.
20. Weiergräber M, Henry M, Hescheler J, Schneider T. 
Ablation of the Ca
V
2.3 containing E-type voltage-gated 
calcium channel results in cardiac arrhythmia and 
altered autonomic control within the murine cardio-
vascular system. Heart Rhythm 2005; 2:35-6.
21. Ackerman MJ. Cardiac channelopathies: it’s in the 
genes. Nat Med 2004; 10:463-4.
22. Choi G, Kopplin LJ, Tester DJ, Will ML, Haglund 
CM, Ackerman MJ. Spectrum and frequency of car-
diac channel defects in swimming-triggered arrhythmia 
syndromes. Circulation 2004; 110:2119-24.
23. Czirják G, Tóth ZE, Enyedi P. Characterization of 
the heteromeric potassium channel formed by K
V
2.1 
and the retinal subunit K
V
8.2 in Xenopus oocytes. J 
Neurophysiol 2007; 98:1213-22.
24. Patel AJ, Maingret F, Magnone V, Fosset M, Lazdunski 
M, Honore E. TWIK-2, an inactivating 2P domain K+ 
channel. J Biol Chem 2000; 275:28722-30.
25. Yajima T, Nagashima H, Tsutsumi-Sakai R, Hagiwara 
N, Hosoda S, Quertermous T, et al. Functional activity 
of the CFTR Cl- channel in human myocardium. Heart 
Vessels 1997; 12:255-61.
26. Abramowitz J, Birnbaumer L. Physiology and 
pathophysiology of canonical transient receptor poten-
tial channels. FASEB J 2009; 23:297-328.
27. Nakayama H, Wilkin BJ, Bodi I, Molkentin JD. 
Calcineurin-dependent cardiomyopathy is activated 
by TRPC in the adult mouse heart. FASEB J 2006; 
20:1660-70.
28. Gaborit N, Le Bouter S, Szuts V, Varro A, Escande D, 
Nattel S, et al. Regional and tissue specific transcript 
signatures of ion channel genes in the non-diseased 
human heart. J Physiol 2007; 582:675-93.
29. Mangoni ME, Couette B, Bourinet E, Platzer J, Reimer 
D, Striessnig J, et al. Functional role of L-type Ca
V
1.3 
Ca2+ channels in cardiac pacemaker activity. Proc Natl 
Acad Sci USA 2003; 100:5543-8.
30. Xiao J, Yang B, Lin H, Lu Y, Luo X, Wang Z. Novel 
approaches for gene-specific interference via manipulat-
ing actions of microRNAs: Examination on the pace-
maker channel genes HCN2 and HCN4. J Cell Physiol 
2007; 212:285-92.
31. Kang D, Mariash E, Kim D. Functional expression of 
TRESK-2, a new member of the tandem-pore K+ chan-
nel family. J Biol Chem 2004; 279:28063-70.
References
1. Felker GM, Shaw LK, O’Connor CM. A standardized 
definition of ischemic cardiomyopathy for use in clini-
cal research. J Am Coll Cardiol 2002; 39:210-8.
2. Kittleson MM, Minhas KM, Irizarry RA, Ye SQ, 
Edness G, Breton E, et al. Gene expression analysis 
of ischemic and nonischemic cardiomyopathy: Shared 
and distinct genes in the development of heart failure. 
Physiol Genomics 2005; 21:299-307.
3. Sanoudou D, Vafiadaki E, Arvanitis DA, Kranias E, 
Kontrogianni-Konstantopoulos A. Array lessons from 
the heart: focus on the genome and transcriptome of 
cardiomyopathies. Physiol Genomics 2005; 21:131-43.
4. Mangoni ME, Nargeot J. Genesis and regulation of the 
heart automaticity. Physiol Rev 2008; 88:919-82.
5. Tiwari S, Zhang Y, Heller J, Abernethy DR, Soldatov 
NM. Atherosclerosis-related molecular alteration of the 
human Ca
V
1.2 calcium channel α
1C
 subunit. Proc Natl 
Acad Sci USA 2006; 103:17024-9.
6. Bibert S, Roy S, Schaer D, Horisberger J-D, Geering K. 
Phosphorylation of phospholemman (FXYD1) by pro-
tein kinases A and C modulates distinct Na,K-ATPase 
isozymes. J Biol Chem 2008; 283:476-86.
7. Fuller W, Eaton P, Bell JR, Shattock MJ. 
Ischemia-induced phosphorylation of phospholemman 
directly activates rat cardiac Na/K-ATPase. FASEB J 
2004; 18:197-9.
8. Berryman M, Bretscher A. Identification of a novel 
member of the chloride intracellular channel gene fami-
ly (CLIC5) that associates with the actin cytoskeleton of 
placental microvilli. Mol Biol Cell 2000; 11:1509-21.
9. Harrell MD, Harbi S, Hoffman JF, Zavadil J, Coetzee 
WA. Large-scale analysis of ion channel gene expres-
sion in the mouse heart during perinatal development. 
Physiol Genomics 2007; 28:273-83.
10. Liu GX, Derst C, Schlichthörl G, Heinen S, Seebohm 
G, Brüggemann A, et al. Comparison of cloned 
K
ir
2 channels with native inward rectifier K+ chan-
nels from guinea-pig cardiomyocytes. J Physiol 2001; 
532:115-26.
11. Sgard F, Charpantier E, Bertrand S, Walker N, Caput 
D, Graham D, et al. A novel human nicotinic recep-
tor subunit, α10, that confers functionality to the 
α9-subunit. Molecular Pharmacology 2002; 61:150-9.
12. Chu P-J, Robertson HM, Best PM. Calcium channel γ 
subunits provide insights into the evolution of this gene 
family. Gene 2001; 280:37-48.
13. Gill SS, Pulidoa OM, Muellera RW, McGuire PF. 
Molecular and immunochemical characterization of the 
ionotropic glutamate receptors in the rat heart. Brain 
Res Bull 1998; 46:429-34.
14. Brundel BJJM, Van Gelder IC, Henning RH, Tieleman 
RG, Tuinenburg AE, Wietses M, et al. Ion channel 
remodeling is related to intraoperative atrial effec-
tive refractory periods in patients with paroxysmal 
and persistent atrial fibrillation. Circulation 2001; 
103:684-90.
15. Ozaita A, Vega-Saenz de Miera E. Cloning of two 
transcripts, HKT4.1a and HKT4.1b, from the human 
two-pore K+ channel gene KCNK4. Chromosomal 
localization, tissue distribution and functional expres-
sion. Mol Brain Res 2002; 102:18-27.
www.landesbioscience.com Channels 107
86. Tsuji Y, Zicha S, Qi X-Y, Kodama I, Nattel S. 
Potassium channel subunit remodeling in rabbits 
exposed to long-term bradycardia or tachycardia: 
Discrete arrhythmogenic consequences related to dif-
ferential delayed-rectifier changes. Circulation 2006; 
113:345-55.
87. Zicha S, Xiao L, Stafford S, Cha TJ, Han W, Varro A, 
et al. Transmural expression of transient outward potas-
sium current subunits in normal and failing canine and 
human hearts. J Physiol 2004; 561:735-48.
88. Lebeche D, Kaprielian R, del Monte F, Tomaselli 
G, Gwathmey JK, Schwartz A, et al. In vivo car-
diac gene transfer of K
V
4.3 abrogates the hypertrophic 
response in rats after aortic stenosis. Circulation 2004; 
110:3435-43.
89. Donahue JK. Gene therapy for cardiac arrhythmias: A 
dream soon to come true? J Cardiovasc Electrophysiol 
2007; 18:553-9.
90. Crambert G, Füzesi M, Garty H, Karlish S, Geering 
K. Phospholemman (FXYD1) associates with 
Na,K-ATPase and regulates its transport properties. 
Proc Natl Acad Sci USA 2002; 99:11476-81.
91. Zhang X-Q, Ahlers BA, Tucker AL, Song J, Wang J, 
Moorman JR, et al. Phospholemman inhibition of the 
cardiac Na+/Ca2+ exchanger: Role of phosphorylation. J 
Biol Chem 2006; 281:7784-92.
92. Qu YS, Isom LL, Westenbroek RE, Rogers JC, Tanada 
TN, Mccormick KA, et al. Modulation of cardiac Na+ 
channel expression in Xenopus oocytes by β1 subunits. 
J Biol Chem 1995; 270:25696-701.
93. Lopez-Santiago LF, Meadows LS, Ernst SJ, Chen C, 
Malhotra JD, McEwen DP, et al. Sodium channel 
Scn1b null mice exhibit prolonged QT and RR inter-
vals. J Mol Cell Cardiol 2007; 43:636-47.
94. Hesse M, Kondo CS, Clark RB, Su L, Allen FL, 
Geary-Joo CTM, et al. Dilated cardiomyopathy is asso-
ciated with reduced expression of the cardiac sodium 
channel Scn5a. Cardiovasc Res 2007; 75:498-509.
95. Deschênes I, Armoundas AA, Jones SP, Tomaselli GF. 
Post-transcriptional gene silencing of KChIP2 and 
Na
V
β1 in neonatal rat cardiac myocytes reveals a func-
tional association between Na and I
to
 currents. J Mol 
Cell Cardiol 2008; 45:336-46.
96. Dulhunty AF, Pouliquin P, Coggan M, Gage PW, Board 
PG. A recently identified member of the glutathione 
transferase structural family modifies cardiac RyR2 
substate activity, coupled gating and activation by Ca2+ 
and ATP. Biochem J 2005; 390:333-43.
97. Ferron L, Davies A, Page KM, Cox DJ, Leroy J, Waithe 
D, et al. The stargazin-related protein γ7 interacts with 
the mRNA-binding protein heterogeneous nuclear 
ribonucleoprotein A2 and regulates the stability of 
specific mRNAs, including Ca
V
2.2. J Neurosci 2008; 
28:10604-17.
98. Tomita S, Chen L, Kawasaki Y, Petralia RS, Wenthold 
RJ, Nicoll RA, et al. Functional studies and distribu-
tion define a family of transmembrane AMPA receptor 
regulatory proteins. J Cell Biol 2003; 161:805-16.
99. Kato AS, Zhou W, Milstein AD, Knierman MD, 
Siuda ER, Dotzlaf JE, et al. New transmembrane 
AMPA receptor regulatory protein isoform, γ-7, dif-
ferentially regulates AMPA receptors. J Neurosci 2007; 
27:4969-77.
100. Hucker WJ, Ripplinger CM, Fleming CP, Fedorov VV, 
Rollins AM, Efimov IR. Bimodal biophotonic imaging 
of the structure-function relationship in cardiac tissue. 
J Biomed Optics 2008; 13:054012.
101. Brazma A, Hingamp P, Quackenbush J, Sherlock G, 
Spellman P, Stoeckert C, et al. Minimum informa-
tion about a microarray experiment (MIAME)-toward 
standards for microarray data. Nat Genet 2001; 
29:365-71.
66. Perez-Reyes E, Cribbs LL, Daud A, Lacerda AE, Barclay 
J, Williamson MP, et al. Molecular characterization of a 
neuronal low-voltage-activated T-type calcium channel. 
Nature 1998; 391:896-900.
67. Niwa N, Yasui K, Opthof T, Takemura H, Shimizu A, 
Horiba M, et al. Ca
V
3.2 subunit underlies the func-
tional T-type Ca2+ channel in murine hearts during the 
embryonic period. Am J Physiol Heart Circ Physiol 
2004; 286:2257-63.
68. Ju Y-K, Chu Y, Chaulet H, Lai D, Gervasio OL, 
Graham RM, et al. Store-operated Ca2+ influx and 
expression of TRPC genes in mouse sinoatrial node. 
Circ Res 2007; 100:1605-14.
69. Biel M. Cyclic nucleotide-regulated cation channels. J 
Biol Chem 2009; 284:9017-21.
70. White TW, Srinivas M, Ripps H, Trovato-Salinaro A, 
Condorelli DF, Bruzzone R. Virtual cloning, functional 
expression and gating analysis of human connexin31.9. 
Am J Physiol Cell Physiol 2002; 283:960-70.
71. Söhl G, Nielsen PA, Eiberger J, Willecke K. Expression 
profiles of the novel human connexin genes hCx30.2, 
hCx40.1 and hCx62 differ from their putative mouse 
orthologues. Cell Commun Adhes 2003; 10:27-36.
72. Dvorakova M, Lips KS, Brüggmann D, Slavikova 
J, Kuncova J, Kummer W. Developmental changes 
in the expression of nicotinic acetylcholine receptor 
α-subunits in the rat heart. Cell Tissue Res 2005; 
319:201-9.
73. Dai S, Hall DD, Hell JW. Supramolecular assemblies 
and localized regulation of voltage-gated ion channels. 
Physiol Rev 2009; 89:411-52.
74. Mueller RW, Gill SS, Pulido OM. The monkey (Macaca 
fascicularis) heart neural structures and conducting 
system: An immunochemical study of selected neural 
biomarkers and glutamate receptors. Toxicol Pathol 
2003; 31:227-34.
75. Perrino C, Rockman HA. Reversal of cardiac remod-
eling by modulation of adrenergic receptors: a new 
frontier in heart failure. Current Opinion in Cardiology 
2007; 22:443-9.
76. Weinberg DH, Trivedi P, Tan CP, Mitra S, 
Perkins-Barrow A, Borkowski D, et al. Cloning, expres-







. Biochem Biophys Res Commun 
1994; 201:1296-304.
77. McCloskey DT, Turnbull L, Swigart P, O’Connell TD, 






mice. J Mol Cell Cardiol 2003; 35:1207-16.
78. Rivard K, Trepanier-Boulay V, Rindt H, Fiset C. 
Electrical remodeling in a transgenic mouse model of 
α
1B
-adrenergic receptor overexpression. Am J Physiol 
Heart Circ Physiol 2009; 296:704-18.
79. Demolombe S, Marionneau C, Le Bouter S, Charpentier 
F, Escande D. Functional genomics of cardiac ion chan-
nel genes. Cardiovasc Res 2005; 67:438-47.
80. Borlak J, Thum T. Hallmarks of ion channel gene 
expression in end-stage heart failure. FASEB J 2003; 
17:1592-608.
81. Moss AJ, Kass RS. Long QT syndrome: from chan-
nels to cardiac arrhythmias. J Clin Invest 2005; 
115:2018-24.
82. Bezzina CR, Wilde AAM, Roden DM. The molecu-
lar genetics of arrhythmias. Cardiovasc Res 2005; 
67:343-6.
83. Nattel S, Burstein B, Dobrev D. Atrial remodeling and 
atrial fibrillation: Mechanisms and implications. Circ 
Arrhythmia Electrophysiol 2008; 1:62-73.
84. Shieh C-C, Coghlan M, Sullivan JP, Gopalakrishnan 
M. Potassium channels: Molecular defects, diseases 
and therapeutic opportunities. Pharmacol Rev 2000; 
52:557-94.
85. Bristow MR, Raynolds MVA, Port JDA, Rasmussen 
RA, Ray PEA, Feldman AM. Reduced beta1 receptor 
messenger RNA abundance in the failing human heart. 
J Clin Invest 1993; 92:2737-45.
47. Mustapha Z, Pang L, Nattel S. Characterization of the 
cardiac KCNE1 gene promoter. Cardiovasc Res 2007; 
73:82-91.
48. Gaborit N, Steenman M, Lamirault G, Le Meur N, Le 
Bouter S, Lande G, et al. Human atrial ion channel and 
transporter subunit gene-expression remodeling associ-
ated with valvular heart disease and atrial fibrillation. 
Circulation 2005; 112:471-81.
49. Mollnau H, Oelze M, August M, Wendt M, Daiber A, 
Schulz E, et al. Mechanisms of increased vascular super-
oxide production in an experimental model of idio-
pathic dilated cardiomyopathy. Arterioscler Thromb 
Vasc Biol 2005; 25:2554-9.
50. Aggarwal A, Esler MD, Socratous F, Kaye DM. 
Evidence for functional presynaptic alpha-2 adrenocep-
tors and their downregulation in human heart failure. J 
Am Coll Cardiol 2001; 37:1246-51.
51. Brede M, Wiesmann F, Jahns R, Hadamek K, Arnolt C, 
Neubauer S, et al. Feedback inhibition of catecholamine 
release by two different α
2
-adrenoceptor subtypes pre-
vents progression of heart failure. Circulation 2002; 
106:2491-6.
52. Kardia S, Kelly R, Keddache M, Aronow B, Grabowski 





-adrenergic receptors influence heart 
failure survival. BMC Med Genet 2008; 9:93.
53. Kitsios G, Zintzaras E. Genetic variation associated 
with ischemic heart failure: A HuGE review and 
meta-analysis. Am J Epidemiol 2007; 166:619-33.
54. Bukauskas FF, Kreuzberg MM, Rackauskas M, 
Bukauskiene A, Bennett MVL, Verselis VK, et al. 
Properties of mouse connexin 30.2 and human connex-
in 31.9 hemichannels: Implications for atrioventricular 
conduction in the heart. Proc Natl Acad Sci USA 2006; 
103:9726-31.
55. Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe 





subpopulations in nonfailing and failing human ventric-
ular myocardium: coupling of both receptor subtypes to 
muscle contraction and selective β
1
-receptor downregu-
lation in heart failure. Circ Res 1986; 59:297-309.
56. Dorn GW, II, Molkentin JD. Manipulating cardiac 
contractility in heart failure: Data from mice and men. 
Circulation 2004; 109:150-8.
57. Barry DM, Trimmer JS, Merlie JP, Nerbonne JM. 
Differential expression of voltage-gated K+ channel 
subunits in adult rat heart: Relation to functional K+ 
channels? Circ Res 1995; 77:361-9.
58. Davies WL, Vandenberg JI, Sayeed RA, Trezise AEO. 
Cardiac expression of the cystic fibrosis transmembrane 
conductance regulator involves novel exon 1 usage to 
produce a unique amino-terminal protein. J Biol Chem 
2004; 279:15877-87.
59. Warth JD, Collier ML, Hart P, Geary Y, Gelband CH, 
Chapman T, et al. CFTR chloride channels in human 
and simian heart. Cardiovasc Res 1996; 31:615-24.
60. Sanguinetti MC, Curran ME, Zou A, Shen J, Specter 
PS, Atkinson DL, et al. Coassembly of K
V
LQT1 and 
minK (IsK) proteins to form cardiac I
KS
 potassium 
channel. Nature 1996; 384:80-3.
61. Restier L, Cheng L, Sanguinetti MC. Mechanisms by 
which atrial fibrillation-associated mutations in the S1 
domain of KCNQ1 slow deactivation of I
Ks
 channels. J 
Physiol 2008; 586:4179-91.
62. Sampson KJ, Terrenoire C, Cervantes DO, Kaba RA, 
Peters NS, Kass RS. Adrenergic regulation of a key 
cardiac potassium channel can contribute to atrial 
fibrillation: evidence from an I
Ks
 transgenic mouse. J 
Physiol 2008; 586:627-37.
63. Vassort G, Talavera K, Alvarez JL. Role of T-type Ca2+ 
channels in the heart. Cell Calcium 2006; 40:205-20.
64. Pitt GS, Dun W, Boyden PA. Remodeled cardiac cal-
cium channels. J Mol Cell Cardiol 2006; 41:373-88.
65. Mangoni ME, Traboulsie A, Leoni A-L, Couette B, 
Marger L, Le Quang K, et al. Bradycardia and slow-





 T-type calcium channels. Circ Res 2006; 
98:1422-30.
